Search clinical trials for: BIBR 1048 MS gelatine capsule

Total 99 results

Boehringer Ingelheim

Completed

Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy Males

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

Healthy
University of Miami

Terminated

Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris

Acne

United States
Boehringer Ingelheim

Completed

Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Boehringer Ingelheim

Completed

Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

BIBR 953 ZW in Healthy Elderly Subjects

Healthy
GlaxoSmithKline

Completed

Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib

Cancer

Australia
Vaderis Therapeutics AG

Recruiting

Assess Safety and Efficacy of VAD044 in HHT Patients

Hereditary Hemorrhagic Telangiectasia (HHT)

United States, Spain, France, Belgium, Netherlands, Italy
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Tolerability of Pharmaton PHL 00747 in Healthy, Young Female Subjects of Child-bearing Potential

Healthy
University of Johannesburg

Completed

Venavine Intensive® in the Treatment of Symptoms Associated With Chronic Venous Insufficiency

Venous Insufficiency

South Africa
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study

Hepatitis C
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453

Hypertension | Chronic Heart Failure

France
Future University in Egypt

Completed

Bioequivalence Study of Esomeprazole in Healthy Adult Subjects Under Fasting Condition

Bioequivalence

Egypt
PhytoTech Therapeutics, Ltd.

Completed

5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers

Healthy Volunteers

Israel
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers

Healthy
Fundació Eurecat
Circe, S.L.

Completed

Oral Bioavailability of a New Formulation of Pterostilbene Cocrystal in Comparison With Its Free Form (BIOPTERO2) (BIOPTERO2)

Biological Availability

Spain
Boehringer Ingelheim

Completed

BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Saisei Pharma

Completed

Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR)

Covid19

Ukraine
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

Healthy
NuRx Pharmaceuticals, Inc.

Unknown

Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia

United States
Boehringer Ingelheim

Completed

Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers

Healthy
University of Johannesburg

Completed

The Efficacy of Venavine Intensive® on the Quality of Life in Females With Chronic Venous Insufficiency

Venous Insufficiency

South Africa
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Dignity Sciences Ltd.

Completed

Oral DS107 in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

Healthy
Azidus Brasil

Suspended

Effectiveness Evaluation of Panax Ginseng, Vitamins and Minerals in Improvement of Stress and Fatigue

Reduction of Stress and Fatigue
Bukwang Pharmaceutical

Terminated

Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials

Hepatitis B

Korea, Republic of
Portland VA Medical Center
National Cancer Institute (NCI); OHSU Knight Cancer Institute; Oregon State University

Completed

Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation (PBroC)

Prostate Cancer Prevention

United States
Boehringer Ingelheim

Completed

BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery

Venous Thromboembolism

Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Italy, Netherlands, Norway, South Africa, Sweden
RMJ Holdings, LLC

Completed

Safety Study of RMJH-111b to Treat Essential Hypertension

Essential Hypertension

United States
University of Florida
Schwabe North America

Completed

Acidophilus Pearls Fecal Recovery Study

Survival of Probiotics During GI Transit | GI Symptoms

United States

3

Subscribe